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Comparison of High-Specific-Activity Ultratrace
123/131I-MIBG and Carrier-Added 123/131I-MIBG
on Efficacy, Pharmacokinetics, and Tissue Distribution
John A. Barrett,1 John L. Joyal,1 Shawn M. Hillier,1 Kevin P. Maresca,1 Frank J. Femia,1 James F. Kronauge,1
Marie Boyd,2 Robert J. Mairs,2 and John W. Babich1
Abstract
Metaiodobenzylguanidine (MIBG) is an enzymatically stable synthetic analog of norepinephrine that when
radiolabled with diagnostic (123I) or therapeutic (131I) isotopes has been shown to concentrate highly in sym-
pathetically innervated tissues such as the heart and neuroendocrine tumors that possesses high levels of
norepinephrine transporter (NET). As the transport of MIBG by NET is a saturable event, the specific activity
of the preparation may have dramatic effects on both the efficacy and safety of the radiodiagnostic/
radiotherapeutic. Using a solid labeling approach (Ultratrace), noncarrier-added radiolabeled MIBG can be effi-
ciently produced. In this study, specific activities of >1200mCi/mmol for 123I and >1600mCi/mmol for 131I have
been achieved. A series of studies were performed to assess the impact of cold carrier MIBG on the tissue
distribution of 123/131I-MIBG in the conscious rat and on cardiovascular parameters in the conscious instrumented
dog. The present series of studies demonstrated that the carrier-free Ultratrace MIBG radiolabeled with either
123I or 131I exhibited similar tissue distribution to the carrier-added radiolabeled MIBG in all nontarget tissues. In
tissues that express NETs, the higher the specific activity of the preparation the greater will be the radiophar-
maceutical uptake. This was reflected by greater efficacy in the mouse neuroblastoma SK-N-BE(2c) xenograft
model and less appreciable cardiovascular side-effects in dogs when the high-specific-activity radiopharmaceutical
was used. The increased uptake and retention of Ultratrace 123/131I-MIBG may translate into a superior diagnostic
and therapeutic potential. Lastly, care must be taken when administering therapeutic doses of the current carrier-
added 131I-MIBG because of its potential to cause adverse cardiovascular side-effects, nausea, and vomiting.
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Introduction
Targetedmolecular radiotherapy is the logical extension ofmolecular diagnostic radionuclide imaging. Treatment
success in cancer depends on sufficient upregulation of dis-
ease target, the specificity of the target, choice of the radio-
nuclide, and a sufficient concentration delivered to and
residence time at the target.1
Metaiodobenzylguanidine (MIBG) is a synthetic analog of
the biogenic amine, norepinephrine, and has been widely
used in its radiolabeled forms (usually 131I or 123I) since the
early 1980s for the diagnosis and, when labeled with iodine-
131, radiotherapy of various neuroendocrine tumors such as
neuroblastoma, pheochromocytoma, and carcinoid. Like
norepinephrine, MIBG is concentrated in sympathomedul-
lary tissues predominantly by an active uptake mechanism,
the norepinephrine transporter (NET).2–4 The NET is ex-
pressed on the surfaces of highly sympathetically innervated
cells of normal tissue, such as the heart and adrenal glands,
and is highly expressed in tumors of neural crest origin, such
as neuroblastoma and pheochromocytoma.2–4 This uptake
and prolonged retention of MIBG within the intracellular
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catecholamine storage vesicles constitute an ideal target/
mechanism to exploit for the detection and treatment of
neuroendocrine tumors because it ensures an increased
concentration and dwell time of the radiodiagnostic/
therapeutic in the tumor.
The current commercial methods to produce 123I- and 131I-
MIBG utilize the copper-catalyzed isotope exchange reaction.
This method requires 1–2mg of nonradioactive MIBG, which
must be present in 2000-fold molar excess to the radioactive
sodium iodide (131I or 123I), coupled with heating the mixture
to 1508C, to drive the halogen exchange to equilibrium. The
radiolabled MIBG is subsequently separated by column
chromatography. Although this is a simple synthesis, it
precludes the ability to produce MIBG with high specific
activity because of the inability to separate nonradiolabeled
MIBG by column chromatography. Vaidyanathan and Za-
lutsky5 developed two routes to synthesize high-specific-
activity MIBG, in which the use of the halogen exchange
reaction was avoided by using nonradiolabeled iodine
for iodine (123 or 131). However, a time-consuming high-
performance liquid chromatography purification is required.
Hunter and Zhu6 have demonstrated a more practical
approach in the use of aryl-tin intermediates, where the
benzylguanidine precursor is bound to a polystyrene-based
resin through a di-butyltin linker. Radiolabeling is per-
formed simply by heating 131I-sodium iodide with an
oxidizing agent and filtering off the radiolabeled MIBG.
The intrinsic implication of this technique is that very high-
specific-activity iodine-labeled radiopharmaceuticals can be
rapidly produced with no other components in the solu-
tion, except the aqueous vehicle. This process offers a true
‘‘carrier-free’’ or ‘‘noncarrier-added’’ radiopharmaceutical
preparation and thus avoids any potential competitive phar-
macological effects of the carrier. Molecular Insight Pharma-
ceuticals, Inc., is developing this true ‘‘carrier-free’’ version of
131I-MIBG as Ultratrace 131I-MIBG.
The present series of studies were performed to compare
the tissue distribution and efficacy of the Ultratrace 123/131I-
MIBG with the carrier-added 123/131I-MIBG.
Materials and Methods
Radiopharmaceuticals
High-specific-activity 123/131I-MIBG was produced by
Molecular Insight Pharmaceuticals via a validated cGMP
process, using the Ultratrace solid phase method. It was
provided as a sterile frozen solution, with a high specific
activity and in radioactive concentration. The Ultratrace
process uses a solid polystyrene resin containing the cova-
lently bound stannylbenzylguanidine precursor, which un-
dergoes a 1:1 displacement reaction with iodine at room
temperature. Briefly, the solid phase precursor is suspended
in a dilute mixture of radioactive 123/131I-sodium iodide,
hydrogen peroxide, and acetic acid at 258C for 60 minutes.
The oxidized 123/131I-iodine reacts to disrupt the covalent
bond between the tin and benzylguanidine precursor with
radioiodine insertion at the meta position of the phenyl ring
to form 123/131I-MIBG. As 123/131I-MIBG forms, it is simul-
taneously cleaved from the solid polymer resin and dissolves
into the liquid phase. The labeled 123/131I-MIBG is then
separated from the remaining solid resin and any residual
reagents by using cation exchange chromatography. The
purified 123/131I-MIBG is eluted from the column and col-
lected in a glass vial containing a solution of sodium genti-
sate and sodium ascorbate acting as radiostabilizers. The
formulated final product solution is filtered through two
0.22-mmmembrane sterilizing filters and 15mL aliquots were
aseptically filled into 30-mL glass vials, which are then
aseptically capped, sealed, and frozen.
The final drug formulation of 123/131I-MIBG was tested
and certified to have a radionuclide purity of >99.0%.
Carrier-added 123/131I-MIBG was made by fortifying 123/131I-
MIBG with the appropriate concentration of cold MIBG to
achieve the desired specific activity. CIS-US 131I-MIBG was
purchased from CIS-US.
123/131I-MIBG rat tissue distribution studies
A quantitative comparison of the tissue distribution and
pharmacokinetics of the carrier-added and the Ultratrace
123I-MIBG or 131I-MIBG was performed in separate groups of
male and female Sprague Dawley rats (N¼ 2 per sex per
group per time point). The test samples were diluted in
phosphate-buffered saline (pH 7.0) and administered via the
tail vein as a bolus of 10mCi/rat (*40mCi/kg) in a constant
volume of 0.1mL. The animals were euthanized by as-
phyxiation with carbon dioxide at 0.25, 1, 6, 24, 48, and
72 hours postinjection. Tissues (heart, liver, lungs, spleen,
large and small intestine [with contents], stomach [with
contents], kidneys, thyroid, skeletal muscle, testes or uterus
and ovaries, brain, bone marrow, and bone) were dissected,
excised, weighed wet, put in plastic tubes, and assayed in an
automated g-counter (LKB model 1282; Wallac Oy). Tissue
time–radioactivity levels of 123/131I-MIBG expressed as per-
cent injected dose per gram (%ID/g) were determined. Blood
samples were also obtained at the time of sacrifice and
weighed, and total radioactivity was determined. Tissue
samples were counted along with aliquots of the injected
dose to correct for radioactive decay and to calculate %ID
contained in each sample. The %ID/g per tissue was calcu-
lated by converting the decay-corrected counts per minute to
the percent dose or the amount of radioactivity in nCi and
then dividing by the weight of the tissue or organ sample.
Cardiovascular effects in conscious dogs
Four (4) male and 4 female beagle dogs were surgically
implanted with telemetry units to permit the assessment of
arterial pressure and heart rate in the conscious free-roaming
state. A gel-filled pressure transducer (for blood pressure
measurements) was inserted into the left femoral artery and
secured appropriately. Two electrocardiogram (ECG) leads
(one positive and one negative) were tunneled through the
subcutaneous tissue to the left ventrolateral thoracic region
(positive lead) and on to the right ventral chest region,
cranial to the manubrium of the sternum and to the right of
the midline (negative lead). Upon completion of a 3-week
postsurgical recovery and acclimation period, each dog was
intravenously (i.v.) administered saline followed by MIBG
in ascending doses of 0.03, 0.3, 1, and 3mg/kg, i.v., at
30-minute intervals and the effects on arterial pressure, heart
rate, and behavior were continuously monitored. The
doses were chosen to encompass the range of total MIBG
administered in human-equivalent therapeutic preparations
of 131I-MIBG.
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131I-MIBG therapy study
Human neuroblastoma xenografts were established in
CD/1nu/nu athymic mice by using the method described
by Rutgers et al.7 A suspension containing 3106 freshly
harvested SK-N-BE(2c) cells was delivered by intrasplenic
injection. When palpable hepatic and splenic tumors devel-
oped, 2–3-mm fragments were placed subcutaneously into
the subcostal flank of new nescient mice. When tumors
reached an average volume of *400mm3, animals were
randomly assigned to one of the treatment groups. Animals
were divided into the following 7 groups (N¼ 8–10 mice per
group): saline, carrier-added 131I-MIBG or noncarrier-added
Ultratrace 131I-MIBG at 8.1, 24.3, and 81mCi/m2 (2.7, 8.1,
and 27mCi/kg). Each animal was administered the test
sample i.v in a volume of 0.1mL, using the schedule outlined
above, for *10 seconds. Tumor dimensions were measured
twice weekly with digital calipers and tumor volumes were
calculated with the following formula: (width2length)/2.
Mice were followed until tumor volumes reached the maxi-
mal allowable size per IACUC guidelines of 1500mm3.
Carrier-added 131I-MIBG, manufactured via the halogen ex-
change method, was purchased from Amersham Biosciences.
It had a specific activity of 8.25mCi/mmol at the time of in-
jection, whereas the Ultratrace 131I-MIBG (ultra) had a spe-
cific activity of 1283mCi/mmol (155-fold increase in specific
activity).
Data analysis
All values were decay corrected to the time of injection
and are expressed as the mean standard deviation or
standard error of the mean. To assess differences between the
groups, statistical analyses consisting of a one-way analysis
of the variance and, where appropriate, Student’s unpaired
t-test (DF¼N 1; two-tailed probability) were performed.
Differences were considered significant when p< 0.05.
The pharmacokinetics of 123/131I-MIBG was analyzed by
WinNonlin 4.1 (Pharsight). The blood and tissue concentration–
time data were computed by a noncompartment method
and PK parameters (Cmax, AUC, and MRT) were generated.
Total organ clearance (CL) was calculated from the follow-
ing equation: CL¼dose/AUC. Steady-state volume of dis-
tribution (Vss) was calculated as follows: Vss¼MRTCL.
Results
Comparison of 123I-MIBG manufactured via
the Ultratrace or the halogen exchange method
A study was conducted in rats to investigate the impact
of cold carrier (carrier added) on the tissue distribution of
123I-MIBG. This was accomplished by comparing the high-
specific-activity (1283mCi/mmol), noncarrier-added 123I-MIBG
prepared via the Ultratrace method to the currently used
halogen exchange method to produce 123I-MIBG with a
specific activity of 8.25mCi/mmol.
Both preparations were cleared from the blood in a similar
manner, and at 72 hours postinjection, blood levels of both
preparations were below the limits of detection (Fig. 1). The
terminal half-life for the carrier-added preparation and the
Ultratrace preparation did not differ (15 and 18 hours,
respectively). There was no significant difference in the Cmax
levels when comparing the preparations in individual tis-
sues. Total radioactivity tissue exposure was determined
using AUC0-inf. A 1.8 times greater exposure was observed in
the heart and lung in the Ultratrace 123I-MIBG-treated ani-
mals when compared with the carrier-added preparation.
Radioactive exposure in the bone marrow tended to be lower
(approximately half ) in the Ultratrace group when compared
with the carrier-added preparation (Fig. 2).
FIG. 1. Blood clearance of 123I-MIBG prepared using the
Ultratrace or the carrier-added method in the conscious rat
administered 40mCi/kg intravenously. The blood concen-
trations are expressed as the mean standard deviation in
nCi/mL decay corrected to the time of injection for 4 rats
each per time point. The specific activity of the Ultratrace
123I-MIBG was 1283mCi/mmol and of the carrier-added
123I-MIBG was 8.25mCi/mmol, which resulted in MIBG
doses of 1.8 and 0.01 mg/kg, respectively. MIBG, metaiodo-
benzylguanidine.
FIG. 2. Tissue exposure of 123I-MIBG prepared using the
Ultratrace or the carrier-added method in the conscious rat
administered 40 mCi/kg intravenously. The AUC0-inf is ex-
pressed as the mean tissue exposure in the conscious rat.
Each histogram is the mean exposure calculated using six
time points with 4 rats per time point. The specific activity of
the Ultratrace 123I-MIBG was 1283mCi/mmol and of the
carrier-added 123I-MIBG was 8.25mCi/mmol, which resulted
in MIBG doses of 1.8 and 0.01 mg/kg, respectively. MIBG,
metaiodobenzylguanidine.
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Figure 3 illustrates the total MIBG content in selected tis-
sues expressed as exposure (AUC). Because of the differences
in specific activity, there was a 300–1000 times greater ex-
posure (heart 26 vs. 10,138 [hourspg]/mL; marrow 1.4 vs.
2145 [hourspg]/mL for the Ultratrace vs. the carrier-added
MIBG, respectively) to tissue of animals administered MIBG
prepared by the carrier-added preparation when compared
with the Ultratrace method.
Comparison of 131I-MIBG manufactured via
the Ultratrace or the halogen exchange method
The tissue distributions of 131I-MIBG prepared using (1)
the Ultratrace method and (2) the iodine exchange, carrier
added, method (CIS-US 131I-MIBG) were assessed in separate
groups of 4 rats each at six time points through 72 hours
postinjection. In the present study, 131I-MIBG was i.v. ad-
ministered at 40mCi/kg (specific activity: Ultratrace
>1600mCi/mmol and Cis 1mCi/mmol). Tables 1 and 2 show
the tissue distributions of 131I-MIBG prepared using the Ul-
tratrace method versus the CIS-US product prepared using
the halogen exchange method. Both 131I-MIBG preparations
were cleared from the blood in a similar manner. After
reaching Cmax (the first time point), blood concentrations
readily declined, with similar residence times of 22.2 and
19.3 hours for the Ultratrace 131I-MIBG and the carrier-added
131I-MIBG, respectively. Mean blood clearance values were
similar for both preparations (0.1 L/[kgh]), indicating that
131I-MIBG is slowly cleared in rats. Blood exposure (AUC0-inf)
was similar for both the Ultratrace (286 hoursnCi/mL) and
the CIS-US (323 [hoursnCi]/mL) preparations. Mean vol-
ume of distribution at steady state (Vss) ranged from 3.1 to
2.4 L/kg for the Ultratrace and the CIS-US groups, respec-
tively. Thus, in a 0.3-kg male rat, Vss would be *1 L, which
is >100% of body weight (assuming that 1 L is equal to 1 kg).
This indicates that 131I-MIBG is highly distributed into deep
tissue compartments.
As anticipated, because of the mechanism of action of
MIBG, uptake and exposure were greatest in the heart.8 After
reaching Cmax at the first time point, heart concentrations de-
clinedwithmean residence times of 12.1 and 11.7 hours for the
Ultratrace 131I-MIBG and the CIS-US 131I-MIBG, respectively.
Mean heart clearance values were similar for both prepara-
tions (0.2 L/[kgh]), indicating that 131I-MIBG was slowly
cleared from the heart in rats. Heart exposure (AUC0-inf) was
similar for both the Ultratrace (2794 [hoursnCi]/mL) and the
carrier-added Cis-US (2460 [hoursnCi]/mL) preparations.
The published literature indicates that the bone marrow is
the dose-limiting organ for the carrier-added 131I-MIBG.9,10
After reaching Cmax, at the first time point (18 and 21 nCi/g
for the Ultratrace and the CIS, respectively), marrow con-
centrations declined, with similar mean residence times of
12.3 and 9.8 hours for the Ultratrace 131I-MIBG and the CIS-
US 131I-MIBG, respectively. Mean marrow clearance values
were similar for both preparations (0.2–0.1 L/[kgh]),
indicating that 131I-MIBG is slowly cleared from the marrow
FIG. 3. Tissue exposure of total MIBG, prepared using the
Ultratrace or the carrier-added method, in the conscious rat
administered 40 mCi/kg intravenously. The AUC0-inf is ex-
pressed as the mean tissue exposure in the conscious rat.
Each histogram is the mean exposure calculated using six
time points with 4 rats per time point. The specific activity of
the Ultratrace 123I-MIBG was 1283mCi/mmol and of the
carrier-added 123I-MIBG was 8.25mCi/mmol, which resulted
in MIBG doses of 1.8 and 0.01 mg/kg, respectively. MIBG,
metaiodobenzylguanidine.
Table 1. Tissue Distribution of Ultratrace 131I-MIBG (Percent Injected Dose per Gram)
Blood Heart Lungs Liver Spleen Kidneysa Adrenalsa Skeletal muscle Bone Bone marrow Brain Thyroid
0.25 Hour 0.20 2.94 4.12 0.45 0.74 1.47 0.71 0.30 0.31 0.17 0.03 0.38
0.02 0.46 0.31 0.07 0.20 1.25 0.46 0.03 0.06 0.06 0.00 0.31
1 Hour 0.14 2.25 1.75 0.29 0.77 0.61 1.07 0.25 0.29 0.13 0.02 1.93
0.02 0.24 0.47 0.11 0.20 0.29 0.87 0.13 0.14 0.03 0.00 1.18
6 Hours 0.10 1.10 0.52 0.10 0.60 0.24 0.44 0.16 0.17 0.10 0.01 5.39
0.02 0.31 0.09 0.03 0.27 0.09 0.31 0.07 0.07 0.05 0.00 4.25
24 Hours 0.02 0.16 0.07 0.02 0.11 0.04 0.51 0.05 0.05 0.00 0.00 8.10
0.00 0.08 0.02 0.01 0.08 0.00 0.27 0.03 0.01 0.00 0.00 3.06
48 Hours 0.01 0.05 0.02 0.01 0.03 0.01 0.23 0.01 0.01 0.00 0.00 10.57
0.00 0.01 0.00 0.00 0.01 0.00 0.10 0.01 0.00 0.00 0.00 10.58
72 Hours 0.01 0.02 0.01 0.01 0.01 0.01 0.09 0.01 0.00 0.00 0.00 5.37
0.00 0.01 0.00 0.00 0.00 0.00 0.10 0.00 0.00 0.00 0.00 3.01
All values are expressed as the percent injected dose/g decay corrected to the time of injection mean standard deviation for 4 rats per
time point.
aSum of paired organs.
MIBG, metaiodobenzylguanidine.
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in rats. Marrow exposure (AUC0-inf) was similar for both the
Ultratrace (202 [hoursnCi]/mL) and the CIS-US (332
[hoursnCi]/mL) preparations. There was no difference be-
tween the preparations observed in the kidney and liver
(Table 3). Thus the bone marrow remains the dose-limiting
organ for the Ultratrace labeling method.
Comparison of blood pharmacokinetics and tissue
distribution of the Ultratrace 131I-MIBG and the cold
carrier MIBG in the conscious rat
To study the implications of the cold carrier MIBG when
therapeutic doses of 131I-MIBG are administered, a tissue
distribution study was conducted in conscious rats, wherein
the specific activity of the test preparations was adjusted to
mimic the amount of cold carrier that would be present at
therapeutic doses in the range of 5–10mCi/kg by using the
specific activity of the current commercially available Izotop
and the previously available Michigan 131I-MIBG products.
In the present study, rats were administered 40 mCi/kg
(240 mCi/m2) Ultratrace fortified with cold MIBG to mimic
doses of 185 and 370mCi/m2 (5 and 10mCi/kg) in man. In
the noncarrier-added Ultratrace group, because of the high
specific activity, the total amount of MIBG administered was
below the limits of quantification. The fortified Ultratrace
131I-MIBG showed comparable blood pharmacokinetics
when compared with the Ultratrace 131I-MIBG (Fig. 4). The
radiolabel was detected at varying levels in all tissues ex-
amined, which decreased readily over time. No difference in
tissue distribution was noted with the exception of the heart
between 46.5 and 93mg/mCi (5 and 10mCi cold carrier
mimic) carrier 131I-MIBG. Increasing amounts of the cold
carrier MIBG resulted in decreased uptake of 131I-MIBG in
the heart (Fig. 4). Notably, when compared with the non-
carrier-added Ultratrace 131I-MIBG, both preparations dem-
onstrated a significant ( p< 0.005) reduction in exposure
(AUC) to 131I-MIBG in the heart. At 6 hours postinjection,
concentrations of 115.05 33.71, 28.40 3.67, and 22.34
4.00 nCi/g were determined for the Ultratrace 131I-MIBG, the
Ultratrace 131I-MIBG plus 46.5mg/mCi, and the Ultratrace
131I-MIBG plus 93mg/mCi, respectively.
The decrease in uptake in the heart with low specific
activity was anticipated because the heart is a highly inner-
vated tissue with high expression of the norepinephrine
Table 2. Tissue Distribution of Cis-US 131I-MIBG (Percent Injected Dose per Gram)
Blood Heart Lungs Liver Spleen Kidneysa Adrenalsa Skeletal muscle Bone Bone marrow Brain Thyroid
0.25 Hour 0.23 3.42 3.16 0.50 0.84 1.08 1.44 0.23 0.20 0.04 0.72 0.23
0.03 0.26 0.33 0.10 0.38 0.61 1.79 0.06 0.11 0.03 0.58 0.03
1 Hour 0.16 2.04 1.44 0.32 0.82 0.57 0.85 0.20 0.21 0.02 1.89 0.16
0.03 0.38 0.45 0.06 0.13 0.35 0.32 0.10 0.16 0.00 1.66 0.03
6 Hours 0.13 0.90 0.42 0.13 0.72 0.23 0.44 0.13 0.17 0.01 7.01 0.13
0.03 0.19 0.05 0.04 0.24 0.03 0.21 0.09 0.07 0.00 6.20 0.03
24 Hours 0.03 0.20 0.09 0.03 0.17 0.06 0.17 0.06 0.03 0.00 19.82 0.03
0.00 0.06 0.01 0.01 0.09 0.01 0.09 0.02 0.06 0.00 18.20 0.00
48 Hours 0.01 0.06 0.03 0.02 0.05 0.02 0.32 0.02 0.00 0.00 10.04 0.01
0.00 0.02 0.01 0.01 0.02 0.00 0.12 0.01 0.00 0.00 9.38 0.00
72 Hours 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 3.84 0.00
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 3.77 0.00
All values are expressed as the percent injected dose/g decay corrected to the time of injection mean standard deviation for 4 rats per
time point.
aSum of paired organs.
MIBG, metaiodobenzylguanidine.
Table 3. Pharmacokinetic Analysis of Ultratrace 131I-MIBG and CIS-US 131I-MIBG in Selected Tissues
Blood Heart Marrow Kidney Liver
Ultratrace 131I-MIBG
Cmax (nCi/g) 21 304 18 144 46
AUC0-inf ([hoursnCi]/mL) 286 2794 202 758 368
Clearance (L/[hkg]) 0.10 0.01 0.20 0.05 0.10
Vss (L/kg) 3.1 — — — —
MRT (hours) 22.2 12.1 12.3 17.9 21.9
CIS-US 131I-MIBG
Cmax (nCi/g) 23 342 21 108 50
AUC0-inf ([hoursnCi]/mL) 323 2460 332 702 428
Clearance (L/[hkg]) 0.10 0.02 0.10 0.06 0.09
Vss (L/kg) 2.4 — — — —
MRT (hours) 19.3 11.7 9.8 14.4 22.2
Analysis was performed using the mean standard deviation for 4 rats at six time points. CIS-US (specific activity: 1mCi/mmol) and
Ultratrace 131I-MIBG (specific activity: >1600mCi/mmol) at 40 mCi/kg were studied in separate groups of 4 rats per time point with six time
points through 72 hours postinjection.
MIBG, metaiodobenzylguanidine.
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uptake-1 transporter. Interestingly, a tendency toward a
dose-related increase in 131I-MIBG uptake in the presence of
increasing amounts of the cold carrier MIBG was observed in
the bone marrow (Figs. 4 and 5).
Impact of MIBG on the cardiovascular system
in the conscious dog
A study was performed to assess the impact of the cold
carrier MIBG on the cardiovascular system (arterial pressure,
heart rate, and ECG) in conscious telemeterized dogs. The
doses were chosen to determine the amount of cold carrier
commonly observed in the current commercially available
131I-MIBG therapeutic products. At a dose of 370mCi/m2,
the resultant amount of MIBG delivered by using the Ul-
tratrace 131I-MIBG was 3mg/kg, whereas by using the Izotop
and University of Michigan products*600–1000 mg/kg was
delivered.
Treatment with MIBG at doses up to 3000mg/kg had no
adverse effect on mortality, clinical, cageside, or postinjection
observations, body weights, body weight changes, body
temperature, or QT values.
A dose-dependant increase in arterial pressure concomi-
tant with a reflex bradycardia was observed in all animals,
with the reflex bradycardia maximized at 1mg/kg, i.v. At
3mg/kg, i.v., the duration of action was >20 minutes. MIBG
at 30, 300, 1000, and 3000 mg/kg, i.v., elicited dose-related
increases in mean arterial pressure of 0%, 13%, 32%, and
45%, respectively, from the baseline value of 108 4mmHg.
A reflex bradycardia was observed, wherein heart rate de-
creased by 8%, 39%, 50%, and 43%, respectively, from the
baseline value of 111 4 bpm (Fig. 6).
All ECGs were within normal limits following bolus in-
travenous administration of MIBG at doses of 30 and
3000 mg/kg.
Comparison of the antitumor effects of the Ultratrace
131I-MIBG and the carrier-added 131I-MIBG
A study was performed in the human neuroblastoma SK-
N-BE(2c) mouse xenograft model to compare the therapeutic
efficacy of the high-specific-activity Ultratrace 131I-MIBG
with the low-specific-activity 131I-MIBG purchased from
Amersham Biosciences. When the tumors reached a starting
volume of 391 8mm3, animals were randomly assigned to
one of the 7 treatment groups. There were no significant
differences in the average starting tumor volume in any of
the treatment groups. Saline treatment resulted in a linear
growth rate over 15 days at which point the animals were
euthanized because of tumor size of >1500mm3. During this
time the tumor size increased fourfold, resulting in a tumor
doubling time of*6 days. The intravenous administration of
a single dose of 8.1, 24.3 and 81mCi/m2 131I-MIBG (2.7, 8.1,
and 27mCi/kg) elicited a dose-related suppression in
growth rate when compared with saline. In all cases the
decrease in tumor growth rate was approximately twofold
greater in the Ultratrace 131I-MIBG groups when compared
with the carrier-added 131I-MIBG groups (Table 4 and Fig. 7).
At 45 days after the administration of 81mCi/m2 (27mCi/
kg) Ultratrace 131I-MIBG, the tumor size increased fourfold
above baseline when compared with the same administered
radioactive dose of the carrier-added 131I-MIBG, wherein a
fourfold increase in growth rate was observed at 28 days
post-treatment.
Discussion
Treatment success of radiopharmaceuticals depends on
sufficient upregulation of the receptor or enzyme in the
disease, the specificity of the target, choice of the radionu-
clide, and a sufficient concentration delivered to and retained
at the target.1 The selective targeted delivery of beta emitters
to the tumor results in the formation of oxygen-derived free
radicals, which interact among themselves to produce ad-
ditional free radicals. The production of oxygen-derived free
radicals is the primary mechanism by which beta radiation
induces biological damage at lower radiation absorbed doses
to the tumor.11,12 Because of their rapid metabolic rate, tumor
cells have developed several defense and repair mechanisms
to deal with the generation of free radicals, the antioxidants
being the primary mechanism. When an appropriate dose of
beta radiation is administered, this primary defense mecha-
nism can be overcome, resulting in the degradation of the
damaged target proteins that culminates with apoptosis of
the irreversibly damaged cells.13,14 Iodine-131 is a desirable
isotope for radiotherapy because it possesses both gamma
energy for the detection of avid lesions and beta energy to
induce tumor cell apoptosis. The targeting moiety described
in this article, MIBG coupled with iodine-131, was chosen for
the treatment of neuroendocrine tumors because MIBG is an
enzymatically stable analog of norepinephrine that has been
shown to concentrate in highly sympathetically innervated
tissues such as the heart and neuroendocrine tumors.15 As
the NET and presynaptic storage granules, as well as chro-
maffin granules, are saturable, the specific activity of the
preparation may have dramatic effects on both the safety and
efficacy of the radiodiagnostic/radiotherapeutic. Using the
Ultratrace method, which removes virtually all of the non-
radiolabeled MIBG, we were able to achieve specific activi-
ties of >1200mCi/mmol for 123I-MIBG and 1600mCi/mmol
for 131I-MIBG. Andreview, a commercially available prepa-
ration of 123I-MIBG, has a specific activity of *1mCi/mmol,
whereas radiotherapeutic preparations of 131I-MIBG have
specific activities between 1 and 10mCi/mmol.
The working hypothesis of the present study is that the
Ultratrace MIBG will have a similar tissue distribution to the
commercially available preparations in tissues with low
sympathetic innervation but have superior uptake and
retention in those that are highly innervated. To test this
hypothesis, the tissue distributions of the Ultratrace 123/131I-
MIBG and the carrier-added 123/131I-MIBG were studied.
In the present study, the Ultratrace 123I-MIBG and the
carrier-added 123I-MIBG showed similar tissue distribution
and pharmacokinetics of radiolabeled compound in most
tissues. For the amount of carrier examined here, in the
carrier-added preparation there was a 300–1000-fold increase
in the transporter exposure to MIBG total mass when com-
pared with the Ultratrace preparation, resulting in, as an-
ticipated, 50% less agonist exposure to the heart compared
with the carrier-added preparation (Figs. 2 and 3). These
results are in agreement with those of Verberne et al.,8 who
demonstrated that decreasing the specific activity from 5.4
to 1.1mCi/mmol resulted in a decrease of *20% in cardiac
radioactive uptake. In addition, the present study assessed
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the impact of MIBG on the cardiovascular system and
demonstrated that i.v. administered MIBG elicited a dose-
related increase in arterial pressure concomitant with a reflex
bradycardia in the normal canine. These results clearly show
that the amount of cold carrier administered not only will
have an impact on ability to accurately study the sympa-
thetic innervation of the diseased heart but also may have
cardiovascular safety implications for increase in blood
pressure. Further, these data are consistent with the hy-
pothesis that MIBG tissue uptake is an active process and
that the cold carrier MIBG competes with 123I-MIBG for
target binding.
The impact of the cold carrier MIBG, administered at
therapeutic levels, on tissue distribution was studied in
normal rats. In the present study, the Ultratrace 131I-MIBG
was fortified with unlabeled MIBG to mimic the total
amount of the cold carrier MIBG in doses of 5 or 10mCi/kg
products currently administered to patients. The amount of
MIBG present at these levels using the Ultratrace 131I-MIBG
was*0.06 mg/kg (5.7 ng/mCi). Similar to what we observed
FIG. 4. Determination of the impact of cold carrier MIBG on blood, heart, and bone marrow clearance in conscious rats. The
mean SD tissue clearance over time for rats administered the Ultratrace 131I-MIBG (40mCi/kg), the commercial CIS-US
131I-MIBG (40 mCi/kg), and the Ultratrace 131I-MIBG (40 mCi/kg) fortified with cold carrier MIBG at therapeutic doses of
185mCi/m2 (cold 46.5mg/mCi) and 370mCi/m2 (cold 93mg/mCi) is depicted. Each point is the mean SD for 4 rats per
time point. MIBG, metaiodobenzylguanidine; SD, standard deviation.
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with the Ultratrace 123I-MIBG, no differences in tissue dis-
tributions in low sympathetic innervated tissues were noted
between 46.5–93mg/mCi carrier-added 131I-MIBG and Cis-
US 131I-MIBG when compared with the noncarrier-added
Ultratrace 131I-MIBG. In the heart, however, when compared
with the Ultratrace 131I-MIBG, a dose-related reduction in
retention of and exposure to 131I-MIBG was observed be-
cause of its high innervation. Similar results were observed
by Mairs et al.,16 who demonstrated, in the mouse, no
changes in tissue distribution of the carrier-added and the
noncarrier-added 131I-MIBG in tissues with low sympathetic
innervation, but a marked reduction in cardiac exposure was
also observed. Interestingly, a trend toward higher levels of
uptake of 131I-MIBG in the bone marrow was noted, with
increasing amounts of the cold carrier MIBG. Similar obser-
vations were made by Boyd et al.,17 who found a lack of
myelosuppression in mouse xenograft studies using the Ul-
tratrace 131I-MIBG. The reason for these findings is poorly
understood. Additional studies to further evaluate this
finding are planned. The results of the cardiovascular as-
sessment in dogs clearly show that care must be taken when
administering the carrier-added 131I-MIBG because at ther-
apeutic doses of between 5 and 10mCi/kg the total amount
of MIBG administered will be between 300 and 1000mg/kg,
whereas in the case of the Ultratrace noncarrier-added
131I-MIBG it will be 0.06 mg/kg. As observed in the canine
cardiovascular assessment, MIBG at 0.06 mg/kg will have no
effect, whereas higher doses of 300 and 1000mg/kg will re-
sult in a marked increase in arterial pressure concomitant
with a reflex bradycardia.
On the basis of the working hypothesis and the results
discussed in the present study, the utilization of the Ultra-
trace 131I-MIBG as a therapeutic agent suggested the possi-
bility of improved tumor kill and increase in the therapeutic
index. To assess this hypothesis, the effects of the Ultratrace
131I-MIBG (specific activity 1283mCi/mmol) and the com-
mercially available carrier-added 131I-MIBG (Amersham
Health specific activity¼ 8.25mCi/mmol) in the human
neuroblastoma SK-N-BE(2c) mouse xenograft model were
studied. Previously, in this model, Mairs et al.16,18 compared
the uptake and retention of the carrier-added and the non-
carrier-added 131I-MIBG at 4.5mCi/kg in the SK-N-BE(2c)
mouse xenograft model. In their study, they observed greater
uptake in the tumor by using the noncarrier-added 131I-
MIBG, which resulted in a tumor radiation absorbed dose
that was 2.3 times greater for the noncarrier-added 131I-
MIBG than for the carrier-added 131I-MIBG. In the present
study, at each comparable administered dose, the Ultratrace
131I-MIBG elicited a greater and more durable reduction in
tumor growth when compared with the identical adminis-
tered dose of the carrier-added 131I-MIBG. These results are
in agreement with the work of Boyd et al.,17 who studied the
effects of the Ultratrace 131I-MIBG (SA 780mCi/mmol) and
the commercially available carrier-added 131I-MIBG (Amer-
sham Biosciences; SA¼ 8.3mCi/mmol) on tumor uptake and
efficacy in vivo by using the UVW/NET mouse xenograft
model. In the present study, comparative imaging of mice
FIG. 6. Effects of intravenously administered MIBG on
mean arterial pressure (A) and heart rate (B); MIBG was ad-
ministered in increasing doses at 20-minute intervals in con-
scious dogs. Each histogram is the mean standard error of
the mean for 8 dogs. At a therapeutic dose of 370mCi/m2, the
resulting amount of MIBG delivered by using the Ultratrace
formulation was 3 mg/kg, whereas by using the Izotop and
University of Michigan formulation 600–1000 mg/kg of MIBG
was delivered. MIBG, metaiodobenzylguanidine. Arrows de-
pict typical mass of MIBG administered at therapeutic doses
of 131I-MIBG.
FIG. 5. Influence of the MIBG specific activity on heart
uptake in the conscious rat at 1 hour postinjection. The mean
heart exposure for rats administered 131I-MIBG (40 mCi/kg)
at a specific activity of 0.002mg/mCi for the Ultratrace and
0.3mg/mCi for the Cis-US, at therapeutic doses of 185mCi/m2
(43mg/mCi) and 370mCi/m2 (93mg/mCi), is depicted.
Each histogram is the mean standard error of the mean
for 4 rats. MIBG, metaiodobenzylguanidine; %ID/g, percent
injected dose per gram.
306 BARRETT ET AL.
administered the commercially available or the Ultratrace
131I-MIBG preparation clearly demonstrated superior in vivo
uptake with the Ultratrace 131I-MIBG when compared with
the carrier-added preparation. In the therapeutic study, a
single dose of either the carrier-added or the Ultratrace 131I-
MIBG showed a dose-related inhibition of tumor growth
with both preparations. In all cases, the Ultratrace 131I-MIBG
was superior to the same dose of commercially available 131I-
MIBG. Notably, a single dose of 20mCi/kg (60mCi/m2) Ul-
tratrace 131I-MIBG resulted in no tumor growth for >47 days.
Conclusions
In summary, the carrier-free Ultratrace MIBG radiolabeled
with either 123I or 131I exhibited similar tissue distribution to
the carrier-added radiolabeled MIBG in all tissues that do not
have high sympathetic innervation. In highly sympatheti-
cally innervated tissues such as the heart and neuroendo-
crine tumors, it was observed that the higher the specific
activity of the preparation the greater will be the radio-
pharmaceutical uptake, which, in the case of a tumor,
translated into a greater and more durable reduction in tu-
mor growth. The targeted increased uptake and retention of
the Ultratrace 123/131I-MIBG as well as reduction in MIBG
mass per dose may translate into a superior diagnostic and
therapeutic activity. These data are consistent with the hy-
pothesis that MIBG tissue uptake is an active process and
that the cold carrier MIBG competes with 123/131I-MIBG for
target binding. Lastly, care must be taken when adminis-
tering therapeutic doses of the current carrier-added 131I-
MIBG products because of their potential to cause adverse
cardiovascular side-effects.
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